Credit: Eton. Khindivi is expected to be available the week of June 2, 2025. Khindivi is the first FDA-approved hydrocortisone oral solution. The Food and Drug Administration (FDA) has approved ...

Credit: Getty Images. Elyxyb is a ready-to-use oral solution formulation of celecoxib, a nonsteroidal anti-inflammatory drug. Scilex Holding Company has announced the relaunch of Elyxyb ™ (celecoxib ...

Cetirizine is used to treat symptoms of respiratory allergies like hay fever and itching due to hives. It is available in multiple forms including tablets, chewable tablets, orally disintegrating ...

Imatinib (Imkeldi) is the first oral liquid TKI approved for multiple cancers, enhancing treatment accessibility and dosing precision. The drug is effective as a first-line treatment, especially in ...

The FDA has assigned a Prescription Drug User Fee Act target date of February 25, 2026 to the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ET-600 ...

Noom, a digital health company for chronic disease prevention, will begin offering oral medications for weight loss through its Noom Med program, it announced Thursday. New York City-based Noom helps ...

BRIDGEWATER, N.J, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of Amneal’s sodium ...

Ondansetron is FDA-approved to help prevent nausea and vomiting in adults receiving chemotherapy, radiation therapy, or having surgery, and in children ages 4 years and older receiving certain types ...

Virbac has acquired Felanorm (methimazole) Oral Solution from Norbrook Laboratories, the animal health pharmaceutical company said in a statement released yesterday. Felanorm is the only FDA-approved ...

Oral medication administration in older adults encompasses a range of challenges and innovative solutions aimed at improving therapeutic outcomes in an ageing population. Age-related physiological ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. The $100 billion obesity market is dominated by injectables, but oral solutions ...